Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.